Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan S Peterson

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Cataract and Refractive Surgery|October 3, 2003
U.s. Code of Federal RegulationsJan S Peterson
Journal of Cataract and Refractive Surgery|February 2, 2010
Specifying methods for mean VA calculationsJan S Peterson
Translational Vision Science & Technology|March 28, 2023
Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and BioactivityJan S Peterson, WeiLiam Chen, Barry M Libin, et al.
Retina (Philadelphia, Pa.)|May 11, 2018
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALSJan S Peterson, Kenneth Rockwell, Ingrid U Scott, et al.
Ophthalmology|May 10, 2005
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case seriesRobert B Nussenblatt, Jan S Peterson, C Stephen Foster, et al.
Journal of Autoimmunity|November 6, 2003
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationRobert B Nussenblatt, Darby J S Thompson, Zhuqing Li, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Cataract and Refractive Surgery|October 3, 2003
U.s. Code of Federal RegulationsJan S Peterson
Journal of Cataract and Refractive Surgery|February 2, 2010
Specifying methods for mean VA calculationsJan S Peterson
Translational Vision Science & Technology|March 28, 2023
Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and BioactivityJan S Peterson, WeiLiam Chen, Barry M Libin, et al.
Retina (Philadelphia, Pa.)|May 11, 2018
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALSJan S Peterson, Kenneth Rockwell, Ingrid U Scott, et al.
Ophthalmology|May 10, 2005
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case seriesRobert B Nussenblatt, Jan S Peterson, C Stephen Foster, et al.
Journal of Autoimmunity|November 6, 2003
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationRobert B Nussenblatt, Darby J S Thompson, Zhuqing Li, et al.
Pageof 1